Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating de-escalated adjuvant treatment approaches in patients with early-stage endometrial cancer that have either POLE mutations or p53 wildtypeno specific molecular profile NSMP. The study compares new tailored treatments against the usual care, which typically involves surgery followed by analysis of tissue to determine the need for additional radiation or chemotherapy. This phase II trial aims to better understand treatment outcomes based on tumor molecular status. Participants may be enrolled in one of two sub-studies EN10.ARAINBO BLUE for POLE-mutated endometrial cancer and EN10.BTAPER for p53 wildtypeNSMP endometrial cancer. Treatments studied include observation alone, observation with adjuvant radiotherapy using external beam radiation or vaginal brachytherapy delivered through specific devices, and other standard radiation methods. These treatments are delivered following surgical removal of the uterus and ovaries, with treatment starting within 10 weeks post-surgery. During the study, participants will be monitored for pelvic, vaginal, para-aortic, and distant recurrences over a three-year period, as well as survival outcomes up to nine years. Researchers will also assess the impact of molecular classification on fear of cancer recurrence using patient-reported questionnaires. Participants will be followed closely at participating centers through scheduled visits and assessments to track treatment effects and safety throughout the study duration.
Actively Recruiting
Researchers are evaluating treatment options for children aged 1 to 18 years with acute, uncomplicated bone and joint infections BJIs, such as osteomyelitis and septic arthritis. This trial aims to determine if using only oral antibiotics is not worse than the standard approach of initial intravenous IV antibiotics followed by oral treatment. The study is conducted across multiple pediatric hospitals in Australia, New Zealand, and Ireland, focusing on full recovery three months after treatment. Children are randomly assigned to one of two treatment groups. One group receives high-dose oral cefalexin four times daily for 1 to 7 days, then a standard dose three times daily for a total of three weeks. The other group follows the standard treatment 1 to 7 days of IV cefazolin or flucloxacillin, then oral cefalexin three times daily for three weeks. The study compares outcomes between these two approaches to see if oral-only treatment is a viable option. Participants will be monitored for recovery and possible complications through assessments at 3, 6, and 12 months after treatment starts. Researchers will evaluate full recovery at three months, recurrence of infection, treatment side effects, and quality of life using several questionnaires. Medication adherence is also tracked. The total study duration extends up to 12 months to observe long-term outcomes and optimize dosing strategies.
Actively Recruiting
This trial investigates treatment options for adults aged 16 to 69 with early-stage classical Hodgkin lymphoma, specifically stage I or II supradiaphragmatic disease without mediastinal bulk or B symptoms. The study compares two chemotherapy regimens ABVD and A2VD, using a PET response-adapted design to adjust therapy based on treatment response. It is a phase III, randomized, open-label trial conducted internationally and sponsored by University College London and Canadian Cancer Trials Group. Participants will be randomly assigned to receive either ABVD chemotherapy doxorubicin, bleomycin, vinblastine, and dacarbazine or A2VD chemotherapy doxorubicin, brentuximab vedotin, vinblastine, and dacarbazine with growth factor support. After two 28-day cycles, a PET-CT scan will assess response using the Deauville score to guide further treatment. Patients with scores 1-3 receive one more cycle those with score 4 receive two more cycles followed by involved site radiotherapy patients with score 5 discontinue trial treatment and receive alternative therapy as determined by their clinician. Throughout the study, participants undergo PET-CT scans and clinical assessments to monitor treatment response and safety. They will be followed for at least five years post-treatment to evaluate progression-free survival and other outcomes such as event-free survival, overall survival, and incidence of second cancers or cardiovascular disease. Safety and toxicity are monitored from treatment start until 30 days after completion. The overall study period extends until 2032.
Actively Recruiting
Researchers are evaluating multiple treatments for community-acquired pneumonia and other respiratory tract infections in hospitalized patients admitted to intensive care. This adaptive platform trial, called REMAP-CAP, aims to identify the effects of various interventions on patient outcomes, including survival and recovery. It also serves as a flexible research platform to study treatments during respiratory pandemics such as COVID-19, with a specific sub-platform called REMAP-COVID for evaluating COVID-19 treatments in the United States. Participants are randomized to receive one or more interventions from various treatment domains including antibiotics, corticosteroids, antivirals, immune modulators, anticoagulation strategies, and mechanical ventilation approaches. Some interventions have been closed to recruitment while others remain active, and dosing or duration often follows local clinical guidelines or specific protocols. The trial uses an adaptive design that allows modification of treatment assignments based on accumulating data and can study interactions between treatments across domains. During the study, hospitalized patients with respiratory infections will be monitored and assessed for outcomes such as 90-day survival and recovery trajectories, days alive without organ support, and quality of life at six months. Data collected include treatment responses, hospital discharge status, and mortality. The trial is designed to continue enrolling patients adaptively over time, with ongoing evaluation of multiple interventions until conclusive answers about their effects are reached.
Actively Recruiting
This observational study focuses on people living with chronic hepatitis B in Australia. It aims to characterize and monitor how individuals link to care and their treatment needs across a wide network of healthcare services. The study is sponsored by the Kirby Institute and seeks to understand various aspects of hepatitis B management in a real-world setting. Participants are individuals diagnosed with chronic hepatitis B who have attended participating clinics for hepatitis B care within the past 12 months or are attending from the study start. There is no intervention as this is an observational study. Data collected includes demographics, lab results, liver disease assessments, treatment history, and clinical management details. Follow-up data will be gathered at each visit or at least every 12 months. During the study, participants will have their hepatitis B treatment and clinical management monitored regularly. Researchers will evaluate outcomes such as hepatitis B disease stage, treatment adherence, liver fibrosis progression, and surveillance for liver cancer. The study plans to collect data until July 2027, with ongoing observation to understand disease progression and care patterns over time.
Actively Recruiting
Healthy Volunteer
This research aims to improve healthcare experiences and outcomes for Aboriginal people by embedding culturally safe healthcare practices and increasing the use of Aboriginal interpreters and health practitioners in Northern Territory hospitals. The study focuses on transforming healthcare culture through anti-racism training and enhancing communication to ensure care is delivered in patients first languages. It also evaluates the impact of these changes on patient outcomes and healthcare provider satisfaction using both quantitative data and qualitative interviews. The study involves implementing a behavioral intervention including anti-racism training called Ask the Specialist Plus, supporting clinical champions of cultural safety through social media and meetings, simplifying interpreter booking processes, and providing training and support to interpreters. Efficiency strategies to improve interpreter availability and retention are tailored to hospital sites. Continuous quality improvement cycles will use data collected through the study to guide ongoing improvements. Participants include Aboriginal patients, interpreters, and healthcare providers who will be involved in interviews, observations, and surveys throughout the study period from 2022 to 2026. Researchers will measure outcomes such as self-discharge rates, patient and provider experiences, interpreter use, hospital readmission rates, and cost-effectiveness. Data will be collected regularly across multiple hospitals to evaluate the interventions impact on cultural safety and healthcare delivery.
Actively Recruiting
Healthy Volunteer
Respiratory syncytial virus RSV causes serious respiratory illness and hospitalizations in young children, especially among Aboriginal and Torres Strait Islander children in Australias Northern Territory. This trial evaluates whether giving a single dose of the RSV-specific monoclonal antibody nirsevimab at around 6 months old can protect these children against RSV infections during their first two years of life. The study uses a pragmatic, randomized controlled design to assess this prevention strategy under real-world conditions. Participants are randomly assigned to receive either one dose of nirsevimab injected into the muscle or standard care without the monoclonal antibody. The dose of nirsevimab is based on the childs weight and given once between 6 months old plus 90 days. Follow-up is mainly passive, using electronic medical records and public health notifications to track RSV infections and hospital visits related to RSV and respiratory illness over 6 and 12 months. The trial also includes an economic evaluation of the interventions cost-effectiveness. At enrollment, basic health and immunization data are collected to confirm eligibility and describe the study population. A brief follow-up call about a week after dosing checks early safety. No extra study visits are required beyond routine healthcare. Researchers will measure RSV infection rates as the primary outcome, along with hospital attendances and admissions related to RSV and respiratory conditions. Passive surveillance will continue up to 12 months after dosing to assess these outcomes, while participants continue their usual healthcare.
Actively Recruiting
This research aims to find out whether an early three-day oral steroid treatment called dexamethasone can improve both physical and mental recovery in children with Sydenhams chorea. Sydenhams chorea is a movement disorder caused by brain inflammation after an abnormal immune response to certain bacterial infections, affecting childrens movements, mood, and concentration. The condition commonly affects children with acute rheumatic fever, and recovery can take months. The study is a phase 3, randomized, double-blinded, placebo-controlled trial involving children in New Zealand and Australia. Participants will be randomly assigned to receive either oral dexamethasone or a placebo for three days. The dexamethasone dose is 20 mg per square meter of body surface per day, divided into three doses, with a maximum of 24 mg per day. The placebo group will take matching capsules on the same schedule. This short course treatment is being tested to see if it reduces the severity of Sydenhams chorea and its psychiatric symptoms. Children in the study will be monitored through scheduled visits on days three, seven, one month, three months, and twelve months. Researchers will assess chorea severity, relapse rates, psychiatric symptoms, hospital stay length, and treatment failure. Safety will be checked for any side effects possibly related to dexamethasone. The trial plans to recruit 80 participants, and overall involvement may last up to 12 months to track recovery and treatment effects comprehensively.